Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality